Nexgel Inc Dossier
Qualitative Analysis
Business overview
NEXGEL, INC. (NASDAQ: NXGL) is a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare, beauty, and over-the-counter (OTC) consumer applications. The company manufactures high-water-content, electron-beam cross-linked, and aqueous polymer hydrogels and gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. NEXGEL operates through two primary segments: Nexgel and CG Labs. Its proprietary hydrogel technology offers distinct advantages, particularly in beauty and medical applications, by providing mess-free, stable, and highly hydrating formulations. The company markets its products under several consumer brands, including Medagel, Kenkoderm, and Silly George, while also maintaining a robust contract manufacturing and white-labeling base.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Establishment of a new surgical division dedicated to housing and commercializing the newly acquired regenerative biomaterials portfolio from Celularity.
Expected impact: Repositions NEXGEL as a growing force in medical technology, tripling annual revenue and establishing immediate profitability.
Appointment of orthobiologics veteran Dave Hazard as Vice President of Sales for the BioNX Surgical division to build scalable sales infrastructure and secure enterprise partnerships.
Expected impact: Accelerates commercial adoption of the regenerative biomaterials portfolio across sports medicine, orthopedics, and spine specialties.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of an exclusive license to Celularity's commercial-stage regenerative biomaterials portfolio, including six established products with existing insurance reimbursement and several development-stage programs.
Financial impact: Expected to triple NEXGEL's annual revenue to approximately $35 million and make the company immediately profitable.
Strategic Partnerships
Sequence LifeScience led the financing to close the Celularity transaction with a $5.5 million strategic investment. Additionally, Sequence's CEO Brian Kieser and COO Kevin Harris were appointed to NEXGEL's Board of Directors to align strategic interests.
Terms: Involved convertible promissory notes and warrants, including a $1.0 million unsecured convertible note issued to Brian Kieser.
Arthrex serves as a key strategic partner for the newly formed BioNX Surgical division, leveraging existing relationships to accelerate product adoption in orthopedic and sports medicine specialties.
Terms: Not disclosed.